Anzeige
Mehr »
Login
Freitag, 09.12.2022 Börsentäglich über 12.000 News von 677 internationalen Medien
Breaking News! Der NYSE IT-Guru & der Cybersecurity-Smallcap!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DXZH ISIN: FR0013280286 Ticker-Symbol: EYWN 
Tradegate
08.12.22
09:30 Uhr
95,00 Euro
-0,96
-1,00 %
1-Jahres-Chart
BIOMERIEUX Chart 1 Jahr
5-Tage-Chart
BIOMERIEUX 5-Tage-Chart
RealtimeGeldBriefZeit
95,5496,2008.12.
95,7296,1808.12.

Aktuelle News zur BIOMERIEUX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.09.Research and Markets: EMEA Gastrointestinal Testing Panels Market Report 2022: Featuring Key Players BD, bioMerieux, DiaSorin, Quidel & Others - ResearchAndMarkets.com327The "Gastrointestinal Testing Panels Market Europe and Middle East Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's...
► Artikel lesen
31.08.Biomerieux H1 Revenue Just Below Expectations; Guidance Slightly Improved409(PLX AI) - Biomerieux half year revenue EUR 1,658 million vs. estimate EUR 1,707 million.• Half year net income EUR 228 million• Outlook FY revenue growth -6 to -3%, up from -7% to -3% previously
► Artikel lesen
16.08.Research and Markets: Global Lateral Flow Assay Market Report to 2029 - Featuring Abbott Laboratories, Danaher and bioMerieux Among Others - ResearchAndMarkets.com604The "Lateral Flow Assay Market Analysis by Application (Drug Development Quality Testing, Testing), by Product (Lateral Flow Readers, Kits Reagents by Technique (Competitive Assays, Sandwich Assays)...
► Artikel lesen
BIOMERIEUX Aktie jetzt für 0€ handeln
12.07.Evotech, Boehringer Ingelheim and bioMérieux launch joint venture to combat antimicrobial resistance7
06.07.Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance8
06.07.Evotec, Boehringer Ingelheim, And BioMérieux Form JV To Fight Antimicrobial Resistance388HAMBURG (dpa-AFX) - Evotec AG(EVO), Boehringer Ingelheim, and bioMérieux, said on Wednesday that they have established a joint venture Aurobac Therapeutics SAS, with an investment of 40 million...
► Artikel lesen
06.07.Evotec SE: Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance462HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical...
► Artikel lesen
06.07.Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance414Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux...
► Artikel lesen
06.07.Biomerieux, Evotec in Antimicrobial Resistance Joint Venture383(PLX AI) - Biomerieux, Boehringer Ingelheim and Evotec launch Aurobac, a joint venture to fight Antimicrobial Resistance.• Funded by Boehringer Ingelheim as lead investor with € 30 m and by Evotec and...
► Artikel lesen
06.07.DGAP-News: Evotec SE: Evotec, Boehringer Ingelheim und bioMérieux gründen Aurobac, ein Joint Venture zur Bekämpfung antimikrobieller Resistenzen682DGAP-News: Evotec SE / Schlagwort(e): Sonstiges Evotec, Boehringer Ingelheim und bioMérieux gründen Aurobac, ein Joint Venture zur Bekämpfung antimikrobieller Resistenzen 06.07.2022...
► Artikel lesen
06.06.Dividendenbekanntmachungen (06.06.2022)4.641 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  2G ENERGY AG  DE000A0HL8N9 - 0,5 EUR  ADL BIONATUR SOLUTIONS SA  ES0184980003 - 0,128 EUR  AIR LEASE CORPORATION  US00912X3026  0,185 USD  0...
► Artikel lesen
19.04.Research and Markets: Global Efficacy Testing Market Trajectory & Analytics Report 2022 Featuring Eurofins Scientific, Merck KGaA, WuXi AppTec, SGS S.A, bioMerieux, Charles River Laboratories, & Pacific Biolabs - ResearchAndMarkets.com744The "Efficacy Testing Global Market Trajectory Analytics" report has been added to ResearchAndMarkets.com's offering. Global Efficacy Testing Market to Reach $796.7 Million by 2026 The global...
► Artikel lesen
12.04.Biomerieux Buys Specific Diagnostics for Price Equivalent to 3.3% of Market Cap421(PLX AI) - Biomerieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution• Says will acquire...
► Artikel lesen
11.04.Biomerieux Q1 Sales Fall 0.9% to EUR 837 Million; FY Guidance Unchanged394(PLX AI) - Biomerieux Q1 sales EUR 837 million.• Q1 organic decline 4.5% at constant FX• FY outlook unchanged• Anticipated headwinds in Immunoassays with lower COVID-related assays demand
► Artikel lesen
02.03.Biomerieux Sees 2022 Sales Falling 3-7%413(PLX AI) - Biomerieux FY revenue EUR 3,376 million.• FY adjusted EBIT EUR 801 million• FY net income EUR 601 million• Sales growth is expected to remain solid in Microbiology and Industry and strong...
► Artikel lesen
06.01.Antabio; bioMérieux; Hospices Civils de Lyon; Toulouse School of Economics: French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance587· ARPEGE is designed to achieve solutions to antibiotic resistance by combining preventive, diagnostic, therapeutic and economic approaches for the first time. · Led by the French...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1